Safety of sorafenib therapy in elderly adults with advanced hepatocellular carcinoma

J Am Geriatr Soc. 2014 Nov;62(11):2204-5. doi: 10.1111/jgs.13091.
No abstract available

Publication types

  • Letter

MeSH terms

  • Activities of Daily Living / classification
  • Adverse Drug Reaction Reporting Systems
  • Age Factors
  • Aged
  • Aged, 80 and over
  • Carcinoma, Hepatocellular / drug therapy*
  • Carcinoma, Hepatocellular / pathology
  • Cohort Studies
  • Dose-Response Relationship, Drug
  • Female
  • Humans
  • Liver Neoplasms / drug therapy*
  • Liver Neoplasms / pathology
  • Male
  • Neoplasm Staging
  • Niacinamide / adverse effects
  • Niacinamide / analogs & derivatives*
  • Niacinamide / therapeutic use
  • Phenylurea Compounds / adverse effects*
  • Phenylurea Compounds / therapeutic use*
  • Sorafenib

Substances

  • Phenylurea Compounds
  • Niacinamide
  • Sorafenib